<DOC>
	<DOCNO>NCT00790777</DOCNO>
	<brief_summary>The purpose study establish bioequivalence paliperidone ER tablet manufacture Gurabo compare paliperidone ER tablet manufacture Vacaville , administer single dose 12 mg fast condition healthy male volunteer , assess safety tolerability formulation .</brief_summary>
	<brief_title>A Study Bioequivalence 12 mg Paliperidone Extended Release Tablets Manufactured Gurabo Vacaville</brief_title>
	<detailed_description>This randomize , open-label , 2-way crossover study healthy male adults.The study consist screen phase open label treatment phase patient receive 2 treatment study drug separate washout period 7 14 day . Treatment A consist single oral dose 12-mg paliperidone ER , tablet manufacture Gurabo , administer fasted condition . Treatment B consist single oral dose 12-mg paliperidone ER , tablet manufacture Vacaville , administer fasted condition . Blood sample pharmacokinetic analysis collect pre-dose 96 hour post-dose period . As change manufacturing site take place , bioequivalence 12 mg tablet ( high dose strength ) 2 production site ( Gurabo [ Puerto Rico , USA ] Vacaville [ California , USA ] ) need demonstrate . This pivotal bioequivalence study design examine pharmacokinetics , safety , tolerability paliperidone ER manufacture Gurabo comparison paliperidone ER manufacture Vacaville Two single oral dos paliperidone ER 12 mg</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Must agree use double barrier method birth control donate sperm study 3 month receive last dose study drug Body mass index ( weight [ kg ] /height [ m2 ] ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg Blood pressure ( patient supine 5 minute ) 100 140 mmHg systolic , inclusive , 50 90 mmHg diastolic Nonsmoker History current significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude volunteer History cancer , exception basal cell carcinoma Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram ( ECG ) screen admission study center At screen , sign autonomic dysfunction indicate decrease &gt; 20 mmHg systolic blood pressure decrease &gt; 10 mmHg diastolic blood pressure stand least 2 minute associated increase &gt; 15 beat per minute ( bpm ) heart rate Bradycardia ( heart rate &lt; 40 bpm ) determine screen 12lead ECG Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol ( acetaminophen ) ibuprofen , within 14 day first dose study drug schedule History , reason believe volunteer history , drug alcohol abuse and/or dependence within past 5 year Known history druginduced dystonia Neuroleptic Malignant Syndrome Positive test human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody History smoking use nicotinecontaining substance within previous 2 month , determine medical history volunteer 's verbal report</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Paliperidone ER</keyword>
	<keyword>Schizophrenia , Mood disorder , Antipsychotic drug</keyword>
</DOC>